Cash FlowCash at June 30, 2025, was $19.8M. The company expects its cash balance, combined with anticipated proceeds from the exercise of in-the-money warrants, to fund operations into Q3 2026.
Financial PerformanceFor Q2 2025, Eupraxia reported a net loss of $8.7M versus $6.1M in Q2 2024, driven by higher R&D and G&A expenses.